Zentalis Pharmaceuticals (ZNTL) Current Assets (2019 - 2026)

Zentalis Pharmaceuticals has reported Current Assets for 8 years, with the latest figure at $218.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 36.39% year-over-year to $218.1 million; the trailing twelve-month figure through Mar 2026 stood at $218.1 million (down 36.39% YoY), and the FY2025 full-year result was $253.2 million, down 34.42% from the prior year.
• Current Assets for Q1 2026 stood at $218.1 million, down from $253.2 million in the prior quarter.
• The five-year high for Current Assets was $563.9 million in Q2 2023, with the low at $218.1 million in Q1 2026.
• Average Current Assets over 5 years is $399.9 million, with a median of $410.2 million recorded in 2023.
• Year-over-year, Current Assets jumped 80.24% in 2022 and sank 36.39% in 2026.
• Tracing ZNTL's Current Assets over 5 years: stood at $451.9 million in 2022, then grew by 9.91% to $496.7 million in 2023, then fell by 22.28% to $386.1 million in 2024, then sank by 34.42% to $253.2 million in 2025, then decreased by 13.86% to $218.1 million in 2026.
• The last three Current Assets figures came in at $218.1 million (Q1 2026), $253.2 million (Q4 2025), and $288.3 million (Q3 2025), per Business Quant data.

Peer Comparison